The Food and Drug Administration (FDA) recently gave Apple the green light to use software that may help million of people ...

This could lead to FDA approvals for treatment in obstructive sleep apnea, kidney disease, Alzheimer’s disease, liver disease ...

Needham analyst Michael Matson has maintained their bullish stance on LIVN stock, giving a Buy rating on October 31. Michael Matson has given ...

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...

I’m sorry to hear your CPAP mask is keeping you awake at night, but I’m happy to hear that you’re addressing your obstructive ...

This could lead to FDA approvals for treatment in obstructive sleep apnea, kidney disease, Alzheimer’s disease, liver disease ...

This could lead to FDA approvals for treatment in obstructive sleep apnea, kidney disease, Alzheimer’s disease, liver disease ...

Think of the heart as a pump that works tirelessly every day. But sometimes, this pump starts to weaken, which is what ...

This could lead to FDA approvals for treatment in obstructive sleep apnea, kidney disease, Alzheimer’s disease, liver disease ...

LivaNova (Nasdaq:LIVN) today announced that its OSPREY trial of nerve stimulation for treating sleep apnea met its primary ...